Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 35 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In 2022, 726 patients were included. The average age was 82.2 years, with a majority of women (68.5%). Most patients were accompanied (85.7%). They had multiple comorbidities and took multiple medications, primarily for cardiovascular diseases. For 613 patients (84.6%), the MMSE score was ≥ 22. In our population, 239 patients (32.9%) were diagnosed “MCI” (Mild Cognitive Impairment), and 147 (20.2%) “Alzheimer’s disease”. The vast majority (95.7%) of patients had undergone MRI. Of the 50 ‘eligible’ patients, 46 had no evidence of AD (amyloid PET or LP). Only 4 patients had undergone Lumbar Puncture, with positive AD biomarkers. None had undergone amyloid PET. Anti-amyloid immunotherapy involves only a small number of Alzheimer elderly patients. Further research is needed. The use of this therapy presents a significant challenge for geriatricians. It seems essential to develop a specific care pathway, create specific multidisciplinary case conferences, and establish a dedicated care pathway.

What this study adds

Evidence grade: Moderate

This is a trial of 726 participants. Among 726 patients in a geriatric memory clinic, only 50 were considered eligible for anti-amyloid immunotherapy, and of those 46 had no evidence of Alzheimer's disease on amyloid PET or lumbar puncture, so none had actually undergone amyloid PET. Reported effect size: 68.5%; 85.7%; 84.6%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Huvent‐Grelle, D., HABIB, N., & Puisieux, F. L. (2025). Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France). La Revue de gériatrie. https://doi.org/10.62581/revgeri.21682

Vancouver

Huvent‐Grelle D, HABIB N, Puisieux FL. Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France). La Revue de gériatrie. 2025. doi:10.62581/revgeri.21682.

BibTeX

@article{huventgrelle2025-972a008a,
  author  = {Huvent‐Grelle, Dominique and HABIB, Nicolas and Puisieux, François L.},
  title   = {{Anti-amyloid immunotherapies for Alzheimer’s disease old people: eligibility and real life in a geriatric memory clinic in Lille (France)}},
  journal = {La Revue de gériatrie},
  year    = {2025},
  doi     = {10.62581/revgeri.21682},
  url     = {https://doi.org/10.62581/revgeri.21682}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

Among 726 patients in a geriatric memory clinic, only 50 were considered eligible for anti-amyloid immunotherapy, and of those 46 had no evidence of Alzheimer's disease on amyloid PET or lumbar puncture, so none had actually undergone amyloid PET. The authors conclude that anti-amyloid immunotherapy applies to only a small number of elderly Alzheimer's patients and that further research and a dedicated care pathway are needed.

Study details

How this study scored 35/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 0 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 2 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record left out, no data; Multicenter collaboration 0 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 34 of the 97 points it could be judged on, which is 35 of 100. Total 35 of 100.34 of the 97 points we could judge = 35 of 100

Published in a peer-reviewed journal. Scored zero for study design and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 34 of the 97 points we could judge it on, which is 35 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (˜La œRevue de gériatrie)
Journal's citation record 0 / 4 La Revue de gériatrie: journal h-index 9 (OpenAlex, 2026-10-29)
Study design 0 / 12 Design recorded as “clinical trial”, which our rubric does not rank (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 2 / 4 726 participants
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author François L. Puisieux: h-index 31 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 0 / 3 OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete)
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 34 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 34 of the 97 points we could judge it on is 35 out of 100.
Total 35 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →